What is new in fungal pharmacotherapeutics?
Approximately 20-25% of the population worldwide is affected by superficial cutaneous mycoses (SCM). SCM are cutaneous fungal infections with a wide array of systemic and topical treatment options. However, successful therapeutic outcomes are limited by patient non-adherence, medication side effects, potential drug interactions, antifungal resistance and disease recurrence. Advances in formulation technology have allowed for the development of more effective and safer therapies. In this article we will review several new and emerging pharmacotherapeutics for onychomycosis and tinea pedis.
Ethan T
ET
Routt
Shelbi C
SC
Jim
Joshua A
JA
Zeichner
Leon H
LH
Kircik
D000499:Allylamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001896:Boron Compounds / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use; D004502:Education, Medical, Continuing; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy*; D014008:Tinea Pedis / Q000188:drug therapy*; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007093:Imidazoles; D014230:Triazoles; D017964:Itraconazole; D000499:Allylamine; C029178:naftifine; C431707:efinaconazole; C512998:tavaborole; C112528:luliconazole